The FDA has approved three applications for first generics of Novartis’ Gilenya (fingolimod) capsules for relapsing forms of multiple sclerosis in adult patients.
Exjade had a market value of roughly $113 million and Jadenu had a market value of about $470 million for the most recent 12 months ended in September.